A real-world feasibility study: at home longitudinal use of the Cumulus NeuLogiq® platform for electrophysiological and neurocognitive measures in patients with mild Alzheimer's Disease dementia - Report - MDSpire

A real-world feasibility study: at home longitudinal use of the Cumulus NeuLogiq® platform for electrophysiological and neurocognitive measures in patients with mild Alzheimer's Disease dementia

  • By

  • Shannon Diggin

  • Laura Rueda-Delgado

  • Alison Buick

  • John F. Dyer

  • Azar Alexander-Sefre

  • Florentine Barbey

  • James B. Rowe

  • Kinan Muhammed

  • Brian T. Harel

  • Bryan J. Hansen

  • Elizabeth Tunbridge

  • Robert Lai

  • David J. Hawellek

  • Ann Marie Hake

  • Hugh Marston

  • Ashwini Oswal

  • Elizabeth Coulthard

  • Vivek Pattan

  • Victoria Evans

  • Stuart Gibson

  • Christopher Kipps

  • Rouba Kozak

  • Nick Mannering

  • Mark Moss

  • Viet Nguyen

  • Kenneth Ruddock

  • Leslie A. Shinobu

  • Sofia Toniolo

  • Brian Murphy

  • June 26, 2026

  • 0 min

Share

Clinical Report: Home-Based NeuLogiq® System for Alzheimer's Assessments

Overview

This study evaluates the usability and feasibility of the Cumulus NeuLogiq® system for cognitive assessments in individuals with mild Alzheimer's disease dementia.

Background

Dementias, particularly Alzheimer's disease, are a leading global health concern, necessitating improved methods for early detection and monitoring. Traditional cognitive assessment tools often suffer from limitations such as rater error and insensitivity to early-stage changes, which can hinder the evaluation of new therapies. The Cumulus NeuLogiq® platform represents a technological advancement that may enhance cognitive assessment through real-world data collection.

Data Highlights

MeasureValue
Overall adherence rate77%
Participants reporting lower confidence levels31.6% (N = 18)
Technical issues during initial setup16.1%

Key Findings

  • Participants with mild Alzheimer's disease demonstrated a 77% adherence rate over 52 weeks.
  • 31.6% of participants reported lower confidence levels in using the platform.
  • 16.1% of reported issues were related to technical challenges during initial home setup.
  • Participants showed strong engagement with the EEG headset and tablet-based tasks.
  • The study highlights the practicality of using the NeuLogiq® platform for long-term assessments in a home setting.

Clinical Implications

The findings suggest that the NeuLogiq® system can be utilized for cognitive assessments in patients with mild Alzheimer's disease.

Conclusion

The Cumulus NeuLogiq® platform demonstrates potential for effective home-based cognitive assessments in individuals with mild Alzheimer's disease, supporting ongoing research and clinical trials.

Related Resources & Content

  1. Conexiant, At-Home Brain Stimulation for Alzheimer’s, 2024 -- https://conexiant.com/neurology/articles/at-home-brain-stimulation-for-alzheimers/
  2. npj Digital Medicine, Systematic Evaluation of Wearable EEG Technology for Identifying Mild Cognitive Impairment, 2026 -- https://www.nature.com/articles/s41746-026-02342-w
  3. Frontiers in Psychiatry, Multimodal non-invasive approaches for early Alzheimer’s disease detection, 2026 -- https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2026.1824430/full
  4. npj Digital Medicine, Smartphone-based detection of subtle memory decline in prodromal Alzheimer’s disease, 2026 -- https://www.nature.com/articles/s41746-026-02731-1
  5. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup, 2024 -- https://pmc.ncbi.nlm.nih.gov/articles/PMC11350039/?utm_source=openai
  6. FDA approves treatment for adults with Alzheimer’s disease, 2024 -- https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease?utm_source=openai
  7. The use of electroencephalography in neurodegenerative disease and its utility in dementia, npj Dementia, 2026 -- https://www.nature.com/articles/s44400-026-00089-5?utm_source=openai
  8. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup - PMC
  9. FDA approves treatment for adults with Alzheimer’s disease | FDA
  10. The use of electroencephalography in neurodegenerative disease and its utility in dementia | npj Dementia

Original Source(s)

A real-world feasibility study: at home longitudinal use of the Cumulus NeuLogiq® platform for electrophysiological and neurocognitive measures in patients with mild Alzheimer's Disease dementia

  • by Shannon Diggin, Laura Rueda-Delgado, Alison Buick, John F. Dyer, Azar Alexander-Sefre, Florentine Barbey, James B. Rowe, Kinan Muhammed, Brian T. Harel, Bryan J. Hansen, Elizabeth Tunbridge, Robert Lai, David J. Hawellek, Ann Marie Hake, Hugh Marston, Ashwini Oswal, Elizabeth Coulthard, Vivek Pattan, Victoria Evans, Stuart Gibson, Christopher Kipps, Rouba Kozak, Nick Mannering, Mark Moss, Viet Nguyen, Kenneth Ruddock, Leslie A. Shinobu, Sofia Toniolo, Brian Murphy

  • June 26, 2026

Related Content

From severity scoring to predictive analytics: the emerging role of AI in neurosurgery

No Short-Term Brain Changes in Youth Soccer

Researchers tracked cognitive, behavioral, imaging, and biomarker outcomes in 129 adolescent athletes across one season.

The role of USP19 in human diseases: from molecular function to clinical relevance